Outlook Therapeutics will resubmit a biologics license application for its ophthalmic formulation of bevacizumab early next year after the second of two clinical trials missed a key target. The ...
Outlook Therapeutics (OTLK) announced preliminary topline results of Norse Eight, the second of two adequate and well controlled clinical ...
Zacks.com on MSN1d
FDA Accepts GSK's BLA for Blenrep Combos in Multiple MyelomaGSK plc GSK announced that the FDA accepted its biologics license application (BLA) seeking approval for the Blenrep ...
Theratechnologies (NASDAQ:THTX) has resubmitted its supplemental Biologics License Application for a simplified dosing formulation of its drug tesamorelin for the reduction of excess abdominal fat in ...
The FDA has received a biologics license application submission for RP1 plus nivolumab in patients with PD-1 ...
The FDA received a biologics license application for accelerated approval of RP1 plus nivolumab for advanced, pretreated ...
The Norse Eight trial was part of the data requested by the FDA after the agency rejected the BLA for the company’s Lytenava ...
Theratechnologies (TSE:TH) has released an update. Don't Miss our Black Friday Offers: Theratechnologies has resubmitted a supplemental Biologics License Application to the FDA for its F8 formulation ...
Omeros ( OMER, Financials) announced progress toward resubmitting its biologics license application for narsoplimab, its ...
Shares of Omeros touched a 52-week high, a day after the company said it could resubmit its biologics license application for narsoplimab to the Food and Drug Administration. In Thursday afternoon ...
London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback